Arkolith/Insider Trading/CTNM/Form 4

Lorrain Daniel S.

Chief Scientific OfficerContineum Therapeutics, Inc. (CTNM) · full profile →Form 4 · filed Feb 26, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$130K
Net Open-Market Flow
-$130K
Transactions
6
4 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 25, 2026Sell(S)4K$16.01$61K156K
Feb 25, 2026Option exercise(M)4K$1.01$4K160K
Feb 24, 2026Option exercise(M)4K$1.01$4K160K
Feb 24, 2026Sell(S)4K$16.03$69K156K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 25, 2026Option exercise(M)4K—$067K
Feb 24, 2026Option exercise(M)4K—$071K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001437749-26-005889) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML